INT176592

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.33
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 8
Disease Relevance 0.41
Pain Relevance 0.05

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Golgi apparatus (PSEN2) endoplasmic reticulum (PSEN2) embryo development (PSEN2)
protein complex (PSEN2) cytosol (PSEN2) peptidase activity (PSEN2)
PSEN2 (Homo sapiens)
Pain Link Frequency Relevance Heat
Glutamate receptor 1 94.20 High High
addiction 19 28.32 Quite Low
depression 1 6.40 Low Low
Pain 4 5.12 Low Low
agonist 29 5.00 Very Low Very Low Very Low
Rsd 24 5.00 Very Low Very Low Very Low
antagonist 12 5.00 Very Low Very Low Very Low
Potency 7 5.00 Very Low Very Low Very Low
alcohol 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Breast Cancer 152 96.00 Very High Very High Very High
Hyperplasia 1 86.24 High High
Sprains And Strains 52 79.44 Quite High
Reprotox - General 1 15 58.00 Quite High
Cancer 37 38.76 Quite Low
Reprotox - General 3 2 20.88 Low Low
Depression 1 6.40 Low Low
Sleep Disorders 1 5.80 Low Low
Arthralgia 1 5.12 Low Low
Apoptosis 89 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Examples of ERE-induced genes include PR, c-fos, bcl-2 and cathepsin D, whereas pS2 and cyclin D1 are transcribed via the activator protein-1 response element.
Transcription (transcribed) of pS2
1) Confidence 0.33 Published 2004 Journal Breast Cancer Res Section Body Doc Link PMC400678 Disease Relevance 0.27 Pain Relevance 0.05
and pS2 mRNA levels were not decreased by decursinol treatment (Figure 5c, lanes 7 and 8 versus lane 2).
Transcription (levels) of pS2
2) Confidence 0.32 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246173 Disease Relevance 0 Pain Relevance 0
mRNA level, the pS2 mRNA level was only modestly decreased by decursin or DA.
Transcription (level) of pS2
3) Confidence 0.31 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246173 Disease Relevance 0 Pain Relevance 0
A suppressing effect of this dose of decursin on the pS2 mRNA level was detectable by 6 hours.
Transcription (level) of pS2
4) Confidence 0.31 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246173 Disease Relevance 0.06 Pain Relevance 0
Positions corresponding to pB, pS1 and pS2 transcription start sites are shown

The pS1 and pS2 promoters are negatively regulated by ppGpp and DksA in vitro

Transcription (transcription) of pS2
5) Confidence 0.06 Published 2010 Journal Mol Genet Genomics Section Body Doc Link PMC2939334 Disease Relevance 0.08 Pain Relevance 0
Positions of transcripts derived from pB, pS1 and pS2 promoters are indicated.
Transcription (derived) of pS2
6) Confidence 0.06 Published 2010 Journal Mol Genet Genomics Section Body Doc Link PMC2939334 Disease Relevance 0 Pain Relevance 0
factors (Fig. 8a).Fig. 8In vitro transcription from the region of the pcnB gene (a) and mapping of the pS2 transcription start sites (b).
Transcription (transcription) of pS2
7) Confidence 0.05 Published 2010 Journal Mol Genet Genomics Section Body Doc Link PMC2939334 Disease Relevance 0 Pain Relevance 0
Although DksA alone was not able to inhibit activities of pS1 and pS2 significantly, this protein enhanced the inhibitory effects of ppGpp, when present together with this nucleotide in the reaction mixture (Fig. 12a–d).Fig. 12Effects of DksA and ppGpp on in vitro transcription from the pS1, pS2 (a–d) and ?
Transcription (transcription) of pS2
8) Confidence 0.05 Published 2010 Journal Mol Genet Genomics Section Body Doc Link PMC2939334 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox